1. Breast Cancer Drug Avastin Faces FDA Panel
... studies concluded that the drug did not make patients live longer. Furthermore, the studies found that Avastin resulted in dangerous side effects, including increased risk of internal bleeding and high blood pressure (Hellerman). Avastin's maker, Genentech, immediately filed an appeal before the FDA Commissioner Margaret Hamburg could finalize the decision. The law that created the "accelerated approval" process, which the drug ... used for polyps in the colon, Mylotarg used by older leukemia patients, and Iressa (Hellerman). In 2004, Avastin was first introduced as cancer therapy becau...
- Word Count: 1317
- Approx Pages: 5
- Has Bibliography
- Grade Level: Undergraduate